AngioDynamics Inc (ANGO) reported a total revenue of $71.1 million for the fourth quarter of fiscal 2024, reflecting a modest year-over-year increase of 2%, driven primarily by a strong performance in the Med Tech segment, which grew by 11%. However, the company's net income showed a continued strain, with a GAAP net loss of $13.4 million. The company's management, led by CEO Jim Clemmer, emphasized the successful execution of strategic initiatives that have transformed their product offerings and market position over the past three years. These developments, particularly in the Med Tech sector, coupled with effective cash flow management, have positioned AngioDynamics to leverage growth opportunities in fiscal 2025, especially with the anticipated FDA clearance for NanoKnife in prostate cancer treatment.